Bruneel, E.

Depypere, Herman

Everaert, Karel

Ghijselings, Lynn

Goessaert, An-Sofie

Pauwaert, Kim

English

Ghent University Academic Bibliography

136 Can hormonal replacement therapy be a solution for postmenopausal women withnocturia?Eur Urol Open Sci 2020;19(Suppl 2):e284Pauwaert K.1, Goessaert A-S.1, Bruneel E.1, Ghijselings L.1, Depypere H.2, Everaert K.11UZ Ghent, Dept. of Urology, Ghent, Belgium, 2UZ Ghent, Dept. of Gynaecology, Ghent, BelgiumIntroduction & Objectives: Nocturia is a common cause in postmenopausal women. Literature suggests an improvement of nocturia by hormonalreplacement therapy (HRT). Nevertheless, nothing is known about the different HRT strategies. The aim of this study is to observe the impact ofdifferent systemic HRT (oral or transdermal estradiol (E2)) in postmenopausal women on nocturia.Materials & Methods: In this controlled, prospective observational trial, all patients were recruited (between March 2015 - June 2019) at thedepartment of gynecology and counselled about HRT. Based on patient’s choice, women were divided in three groups of HRT: no HRT (NH),substitution through oral E2 in combination with progesterone (OE) and transdermal E2 in combination with progesterone (TE). All womencompleted the ICI questionnaire on nocturia or LUTS (ICIQ-N or ICIQ-FLUTS) twice: at baseline and 6 months after initiating treatment. Moreover,bother linked with nocturia was reported on a VAS-scale, with ‘0’ as having no bother and ‘10’ with high bother. Nocturia was defined as ≥2 nocturnalvoids. Descriptive statistics are presented as median (interquartile range). Comparisons were performed using McNemar test for categoricalvariables or Wilcoxon signed-rank test for continuous variables. A p-value <0.05 was considered statistically significant. This study was approvedby the local ethics committee (EC2014/1241, EC2018/0315).Results: In total, 146 women with a median (IQR) age of 53 (50–56) years, were enrolled. Thirty-five did not opt for therapy, 67 favored OE and44 chose TE. Median follow-up time was 5 (2–6) months. Baseline characteristics were similar between the different groups. Initially, 11% (4/35)patients with NH, 27% (18/67) with OE and 23% (10/44) with TE suffered from nocturia. After follow-up, this percentage decreased significantly(p<0.001) for patients with OE substitution to 12% (8/67). In contrast, no significant reduction was seen in patients using NH (p=1) and TE (p=0.01),as the presence of nocturia decreased to 6% (2/35) and 14% (6/44) respectively. Moreover, patients who suffered from nocturia at baseline,reported a significant decrease in bother, linked to nocturia, in both treatment groups (p=0.004 for OE and p=0.02 for TE). At baseline, a medianVAS of 6 (4.0–7.5) and 5 (2.5–6.5) was reported by patients in the OE and TE group respectively. This bother decreased to 3.0 (1.0–5.0) for OEand 1.5 (0.0–4.0) for TE. No improvement of this bother score was seen in the NH group.Conclusions: This analysis shows that HRT is a promising treatment for nocturia in postmenopausal women. In this small cohort, oral E2in combination with systemic progesterone reduced the number of nocturnal voids significantly. In both treatment groups, patients reported asignificant lower bother connected with nocturia. However, a RCT is necessary to confirm this findings.Abstracts EAU20 Virtual Congress and Theme WeekEur Urol Open Sci 2020;19(Suppl 2):e284

Can hormonal replacement therapy be a solution for postmenopausal women with nocturia?

https://biblio.ugent.be/publication/8670787/file/8682930.pdf

Can hormonal replacement therapy be a solution for postmenopausal women with nocturia?

Abstract

Similar works

Full text

Available Versions

Ghent University Academic Bibliography